Empowering Genomics With Proteomics: The Advantages of Adding Protein-Level Data
The rise of genomics has transformed life sciences research, providing powerful tools for exploring all manner of biological questions. More recently, advances in protein analysis have made it feasible to analyze the proteome with a throughput and depth of coverage compatible with genomic techniques. The ability to measure proteins at such scale makes it possible to add proteomics to genetic analyses, allowing researchers to extract new insights from genomic datasets and mine additional value from the immense investments made in the field.
Please join us to hear four experts discuss the present challenges and opportunities for using proteomics to power interpretation of genomic data: Melissa Miller, director, human genetics at Pfizer; Chris Whelan, director, neuroscience data science at Johnson & Johnson; Benjamin Sun, head of biomarker genetics at Biogen; and Anders Mälarstig, director of human genetics and computational biomedicine at Pfizer and an affiliate researcher at the Karolinska Institute.
The panelists will discuss topics including how adding circulating protein data to genomic analyses can yield new understanding of complex biology, including around mechanisms of action of drugs and drug pathways and in identifying new biomarkers for drug candidates and drug repurposing.
Anders Mälarstig, PhD Director of Human Genetics and Computational Biomedicine, Pfizer Affiliate Researcher, Karolinska Institute
Melissa Miller, PhD Director, Human Genetics Pfizer
Benjamin Sun, MD, PhD Head of Biomarker Genetics Biogen
Chris Whelan, PhD Director, Neuroscience Data Science The Janssen Pharmaceutical Companies of Johnson & Johnson